Martingale Asset Management L P Has $21.20 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Martingale Asset Management L P lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 10.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 229,502 shares of the biopharmaceutical company's stock after selling 26,008 shares during the period. Martingale Asset Management L P's holdings in Gilead Sciences were worth $21,199,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in GILD. HHM Wealth Advisors LLC raised its stake in shares of Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 154 shares in the last quarter. YANKCOM Partnership acquired a new position in shares of Gilead Sciences in the 4th quarter valued at $28,000. Decker Retirement Planning Inc. bought a new position in shares of Gilead Sciences during the 4th quarter worth about $29,000. Crews Bank & Trust acquired a new stake in shares of Gilead Sciences during the 4th quarter valued at about $31,000. Finally, Stephens Consulting LLC increased its stake in Gilead Sciences by 325.0% in the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock valued at $31,000 after acquiring an additional 260 shares during the period. 83.67% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Wells Fargo & Company increased their target price on Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. BMO Capital Markets increased their price objective on Gilead Sciences from $110.00 to $115.00 and gave the stock an "outperform" rating in a research note on Wednesday, February 12th. Oppenheimer boosted their target price on shares of Gilead Sciences from $115.00 to $132.00 and gave the company an "outperform" rating in a research note on Tuesday, March 4th. Piper Sandler increased their target price on shares of Gilead Sciences from $105.00 to $110.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 12th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, February 12th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat, Gilead Sciences presently has an average rating of "Moderate Buy" and an average target price of $105.12.

Remove Ads

Gilead Sciences Trading Up 2.2 %

Gilead Sciences stock traded up $2.23 during mid-day trading on Friday, hitting $103.63. 8,683,683 shares of the company's stock were exchanged, compared to its average volume of 7,501,106. The company's 50 day simple moving average is $108.34 and its 200-day simple moving average is $96.89. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The firm has a market capitalization of $129.04 billion, a P/E ratio of 280.08, a PEG ratio of 0.71 and a beta of 0.32. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. On average, equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Friday, March 14th were issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 3.05%. The ex-dividend date was Friday, March 14th. This is a boost from Gilead Sciences's previous quarterly dividend of $0.77. Gilead Sciences's dividend payout ratio is 854.05%.

Insider Buying and Selling at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 142,180 shares of the stock in a transaction on Friday, January 31st. The shares were sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the completion of the transaction, the chief financial officer now owns 129,873 shares in the company, valued at approximately $12,626,253.06. This represents a 52.26 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have sold 302,785 shares of company stock valued at $30,503,250 in the last 90 days. 0.16% of the stock is currently owned by company insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.